Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance

• Published in: Pathology Research International Vol. 2011; no. 2011; pp. 751 - 758
• Main Authors: Mynarcik, Dennis C., McNurlan, Margaret A., Melendez, Mark M., Vosswinkel, James A., Gelato, Marie C.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 12.04.2011; Hindawi Puplishing Corporation; SAGE-Hindawi Access to Research; John Wiley & Sons, Inc
• Subjects: Complications and side effects; Dosage and administration; Drug therapy; Gene expression; Genetic aspects; HIV patients; Insulin resistance; Muscles; Physiological aspects; Rosiglitazone maleate; United States
• ISSN: 2090-8091; 2042-003X; 2042-003X
• DOI: 10.4061/2011/736425

Rosiglitazone, an agonist of peroxisome proliferator activated receptor (PPARγ), improves insulin sensitivity by increasing insulin-stimulated glucose uptake into muscle tissue. This study was undertaken to assess changes in expression of PPAR-regulated genes in muscle tissue following treatment of HIV-associated insulin resistance with rosiglitazone. Muscle gene expression was assessed in twenty-two seronegative HIV subjects (control), 21 HIV-infected individuals with normal insulin sensitivity (HIV-IS) and 19 HIV-infected individuals with insulin resistance (HIV-IR). A subset of the HIV-IR group (N=10) were re-evaluated 12 weeks after treatment with 8 mg/d of rosiglitazone. The HIV-IR group's rosiglitazone-mediated improvement in insulin sensitivity was highly correlated with increased expression of PPARγ and carnitine palmitoyl transferase-1 (CPT-1), (r=0.87, P<.001) and (r=0.95, P<.001), respectively. The changes in PPARγ expression were also correlated with the changes in CPT1 expression (r=0.75, P=.009). The results suggest that rosiglitazone; may have a direct effect on muscle tissue to improve insulin sensitivity.